SOPs for the CMD mouse model LAMA2dy-W
- Raffaella Willmann Raffaella Willmann studied Biology in Italy and obtained her PhD in Biochemistry in Konstanz (Germany)....
- Anne Rutkowski Dr Anne Rutkowski is a practising board-certified emergency medicine physician in Los Angeles. Anne's...
Standard protocols
Cure CMD and TREAT-NMD are collaborating in establishing standard protocols for efficacy studies in the laminin deficient mouse model LAMA2dy-W, the best described mouse model for a CMD disease. Readout parameters in mice were selected that are appropriate to show the efficacy of a new potential drug, and that are related to patient outcomes. For each of these parameters, small groups of experts will develop a standard assessment protocol. The availability of standard protocols will implement research and increase the comparability of results.
The SOPs that have already been completed can be downloaded from this site and others will be added in the future. The last date each SOP was reviewed can be found under the code on the left of the page.
LAMA2dy-W Model |
|||
|
MDC1A_M.1.2.001 |
Assessment of peripheral nerve pathology in laminin-alpha-2-deficient mice |
||
| MDC1A_M.1.2.002 13 June 2012 |
Markus A. Rüegg | ||
|
MDC1A_M.1.2.003 |
Markus A. Rüegg | ||
|
MDC1A_M.1.2.004 |
Histopathology in Hematoxylin & Eosin stained muscle sections |
Markus A. Rüegg | |
|
MDC1A_M.1.2.005 |
Dean Burkin | ||
| MDC1A_M.2.1.001 19 June 2012 |
Recommendations on the care and handling of the MDC1A mouse model dyW |
Janice Dominov | |
Stay up to date with our operating procedures
Disclaimer: TREAT-NMD and the authors of the SOPs disclaim, without limitation, all liability for any loss or damage of any kind, including any direct, indirect or consequential damages, which might be incurred in connection with the information and procedures contained in these SOPs.
